Why the study?
What is the incidence of adverse events associated with captopril in a real-world post-marketing surveillance population?
Population
4,124 patients in New Zealand treated with captopril for hypertension and heart failure
Comparison
Captopril vs Control population (for taste disturbance survey)
Design
Cohort
Follow-up
4 years
Authors
Loading...
Low adverse event rates with captopril in surveillance; supports ongoing monitoring but leaves comparative safety versus other ACE inhibitors open.
What is the incidence of adverse events associated with captopril in a real-world post-marketing surveillance population?
Four years of post-marketing surveillance in New Zealand demonstrated a low incidence of adverse effects for captopril, supporting its safety in treating mild hypertension and early cardiac failure.
Edwards et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: